278 related articles for article (PubMed ID: 16449978)
1. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Herman JF; Mangala LS; Mehta K
Oncogene; 2006 May; 25(21):3049-58. PubMed ID: 16449978
[TBL] [Abstract][Full Text] [Related]
2. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells.
Mangala LS; Fok JY; Zorrilla-Calancha IR; Verma A; Mehta K
Oncogene; 2007 Apr; 26(17):2459-70. PubMed ID: 17043648
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
4. Implications of tissue transglutaminase expression in malignant melanoma.
Fok JY; Ekmekcioglu S; Mehta K
Mol Cancer Ther; 2006 Jun; 5(6):1493-503. PubMed ID: 16818508
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells.
Chen SH; Lin CY; Lee LT; Chang GD; Lee PP; Hung CC; Kao WT; Tsai PH; Schally AV; Hwang JJ; Lee MT
Anticancer Res; 2010 Oct; 30(10):4177-86. PubMed ID: 21036738
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis.
Yu ST; Chen TM; Chern JW; Tseng SY; Chen YH
Anticancer Drugs; 2009 Jun; 20(5):382-8. PubMed ID: 19318911
[TBL] [Abstract][Full Text] [Related]
7. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
Kotsakis P; Wang Z; Collighan RJ; Griffin M
Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Mehta K; Fok J; Miller FR; Koul D; Sahin AA
Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
11. Enhanced osteoblast adhesion on transglutaminase 2-crosslinked fibronectin.
Forsprecher J; Wang Z; Nelea V; Kaartinen MT
Amino Acids; 2009 Apr; 36(4):747-53. PubMed ID: 18604470
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
Mehta K; Kumar A; Kim HI
Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
[TBL] [Abstract][Full Text] [Related]
13. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells.
Nakagawa Y; Nakayama H; Nagata M; Yoshida R; Kawahara K; Hirosue A; Tanaka T; Yuno A; Matsuoka Y; Kojima T; Yoshitake Y; Hiraki A; Shinohara M
Int J Oncol; 2014 Apr; 44(4):1376-84. PubMed ID: 24452447
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase promotes or suppresses tumors depending on cell context.
Chhabra A; Verma A; Mehta K
Anticancer Res; 2009 Jun; 29(6):1909-19. PubMed ID: 19528447
[TBL] [Abstract][Full Text] [Related]
16. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
17. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.
Wang Z; Collighan RJ; Gross SR; Danen EH; Orend G; Telci D; Griffin M
J Biol Chem; 2010 Dec; 285(51):40212-29. PubMed ID: 20929862
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
19. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).
Hazlehurst LA; Damiano JS; Buyuksal I; Pledger WJ; Dalton WS
Oncogene; 2000 Sep; 19(38):4319-27. PubMed ID: 10980607
[TBL] [Abstract][Full Text] [Related]
20. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.
Satpathy M; Cao L; Pincheira R; Emerson R; Bigsby R; Nakshatri H; Matei D
Cancer Res; 2007 Aug; 67(15):7194-202. PubMed ID: 17671187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
